Wolff M, Fandrey J, Jelkmann W, Hirner A
Klinik und Poliklinik für Chirurgie, Rheinische Friedrich-Wilhelms-Universität Bonn.
Langenbecks Arch Chir Suppl Kongressbd. 1996;113:143-5.
The combination of autologous blood donation and rHuEPO therapy is rarely justified for medical and economic reasons. Adequate alternative indications for the use of rHuEPO perioperatively have yet to be studied. Therefore, in addition to the increasing costs of safe homologous blood products and the decreasing costs of recombinant proteins, a reevaluation of the cost-effectivity relationship will be mandatory for rHuEPO in surgery.
出于医学和经济原因，自体献血与重组人促红细胞生成素（rHuEPO）疗法联合使用的合理性很少。围手术期使用rHuEPO的充分替代指征尚待研究。因此，除了安全的同源血制品成本增加以及重组蛋白成本降低之外，对手术中rHuEPO的成本效益关系进行重新评估将是必要的。
